Reduced vascular response to phenylephrine during exposure to lipopolysaccharide in vitro involves nitric oxide and endothelin 1

Shock

Volumn 29, Issue 3, 2008, Pages 417-421

  Scicluna, Johann K ^a   Mansart, Arnaud ^a   Ross, Jonathan J ^a   Reilly, Charles S ^a   Brown, Nicola J ^a   Brookes, Zoë L S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bosentan; Lipopolysaccharide; Myograph; Nitric oxide; Rat arteries

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN 1 RECEPTOR; LIPOPOLYSACCHARIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MALE; NONHUMAN; RAT; SAPHENOUS NERVE; VASOCONSTRICTION;

ANIMALS; ENDOTHELIN-1; ENZYME INHIBITORS; LIPOPOLYSACCHARIDES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHENYLEPHRINE; RATS; RATS, WISTAR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 39449094311     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318142c5df     Document Type: Article

References (39)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273(2):117-123, 1995.
2. Battistini B, Forget MA, Laight D: Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Shock 5(3):167-183, 1996.
3. Kilbourne R: The discovery of nitric oxide as a key mediator in septic shock. Sepsis 1:85-91, 1998.
4. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, Lundberg JM: Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 213(3):261-264, 1991.
5. Theimermann C: Nitric oxide and septic shock. Gen Pharmacol 29(2):159-166, 1997.
6. Sugiura M, Inagami T, Kon V: Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun 161:1220-1227, 1989.
7. Nakaki T, Otsuka Y, Nakayama M, Kato R: Endothelium-accelerated hyporesponsiveness of norepinephrine-elicited contraction of rat aorta in the presence of bacterial lipopolysaccharide. Eur J Pharmacol 219(2):311-318, 1992.
8. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105(3):575-580, 1992.
9. Ignarro LJ: Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters. Pharm Res 6(8):651-659, 1989.
10. Rapoport RM, Draznin MB, Murad F: Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 10-16:174-176, 1983.
11. Connelly L, Madhani M, Hobbs AJ: Resistance to endotoxic shock in endothelial nitric oxide synthase (eNOS) knockout mice. J Biol Chem 280:10040-10046, 2005.
12. Liu SF, Adcock M, Old R, Barnes PJ, Evans TW: Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit Care Med 24(7):1219-1225, 1996.
13. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1998.
14. A sub-type. Br J Pharmacol 114:1110-1116, 1995.
15. B receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873, 1992.
16. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89(3):1203-1208, 1994.
17. Pollock DM: Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Clin Exp Pharmacol Physiol 26(3):258-261, 1999.
18. De Nucci G, Thomas R, D'orleans-Juste P, Antunes E, Walder C, Warner T, Vane R: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85:9797-9800, 1988.
19. Simonson MS, Dunn MJ: The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med 119:622-639, 1992.
20. Iskit AB, Guc O: Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia, and survival in experimental models of septic shock. Acta Pharmacol Sin 24(10):953-957, 2003.
21. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101(3):746-752, 1990.
22. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235, 1994.
23. Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol Rev 70(4):921-961, 1990.
24. Schneider F, Bucher B, Schott C, Andre A, Julou-Schaeffer G, Stoclet J: Effect of bacterial lipopolysaccharide on function of rat small femoral arteries. Am J Physiol 266(1 Pt 2):191-198, 1994.
25. Nunokawa Y, Ishida N, Tanaka S: Cloning of inducible nitric oxide synthase in rat vascular smooth muscle cells. Biochem Biophys Res Commun 191(1):89-94, 1993.
26. Buga G, Griscavage J, Rogers N, Ignarro L: Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 73:808-812, 1993.
27. Ravichandran LV, Johns RA, Rengasamy A: Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol 268(6 Pt 2):H2216-H2223, 1995.
28. Iskit AB, Guc O: The timing of endothelin and nitric oxide inhibition affects survival in amicemodel of septic shock. Eur J Pharmacol 414(2-3):281-287, 2001.
29. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, et al.: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81(4):641-650, 1995.
30. Nakamura T, Kasai K, Sekiguchi Y, Banba N, Takahashi K, Emoto T, Hattori Y, Shimoda S: Elevation of plasma endothelin concentrations during endotoxin shock in dogs. Eur J Pharmacol 205(3):277-282, 1991.
31. Ishimaru S, Shichiri M, Mineshita S, Hirata Y: Role of endothelin-1/endothelin receptor system in endotoxic shock rats. Hypertens Res 24(2):119-126, 2001.
32. Yamaguchi N, Jesmin S, Zaedi S, Shimojo N, Maeda S, Gando S, Koyama A, Miyauch T: Time-dependent expression of renal vaso-regulatory molecules in LPS-induced endotoxemia in rat. Peptides 27(9):2258-2270, 2006.
33. Giardina JB, Green GM, Rinewalt AN, Granger JP, Khalil RA: Role of endothelin B receptors in enhancing endothelium-dependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension 37(2 Part 2):516-523, 2002.
34. B receptors on the liver dysfunction and injury caused by endotoxemia in the rat. Br J Pharmacol 119(3):479-486, 1996.
35. Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E: Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counter-acted by the endothelin receptor antagonist bosentan. Shock 7:364-370, 1997.
36. A receptor antagonist, SB 234551, on the cardiovascular responses to endotoxemia in conscious rats. Br J Pharmacol 133(8):1371-1377, 2001.
37. B receptor antagonism during endotoxin shock. Eur J Pharmacol 386:235-245, 1999.
38. Hirata Y, Ishimaru S: Effects of endothelin receptor antagonists on endothelin-1 and inducible nitric oxide synthase genes in a rat endotoxic shock model. Clin Sci (Lond) 103(Suppl 48):332-335, 2002.
39. Rinaldi GJ: Influence of several methodological procedures utilized to obtain in vitro vascular preparations on endothelial activity. Endothelium 8(4):235-242, 2001.